文献速递药疹与重症皮肤不良反应

SJS/TEN住院死亡率风险预测模型ABCD-10的建立与验证

Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.
PubMed 文献 · JAMA Dermatol · 2019-01-01

IMPORTANCE: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of severe mucocutaneous drug reaction associated with significant morbidity and mortality.…

要点

  • ABCD-10评分基于年龄≥50岁、表皮剥脱>10% BSA、碳酸氢盐<20 mmol/L、活动性癌症和入院前透析。
  • 该模型需在其他人种中验证,未来或为当代患者提供预后信息。

核心结论

  • ABCD-10能准确预测SJS/TEN住院死亡率,区分度与SCORTEN无显著差异。

研究设计与样本

  • 多中心队列研究,纳入美国18个医疗中心2000年1月1日至2015年6月1日治疗的370例18岁及以上SJS/TEN患者,基于其中数据推导风险模型。

主要发现

  • 370例患者平均年龄49.0(标准差19.1)岁,女性195例(52.7%),54例(15.14%)住院期间死亡。
  • 入院时5个独立预测因素:年龄(OR 1.05,95%CI 1.02-1.07)、表皮剥脱BSA百分比(OR 1.02,95%CI 1.01-1.04)、血清碳酸氢盐<20 mmol/L(OR 2.90,95%CI 1.43-5.88)、活动性癌症(OR 4.40,95%CI 1.82-10.61)、入院前透析(OR 15.94,95%CI 3.38-66.30)。

关键数值与推荐

  • ABCD-10评分:年龄≥50岁、表皮剥脱>10% BSA、血清碳酸氢盐<20 mmol/L各计1分;活动性癌症计2分;入院前透析计3分。

临床怎么用

  • ABCD-10可用于SJS/TEN患者入院时住院死亡风险预测,辅助临床决策。

局限性

  • 需在其他人种中验证ABCD-10模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of severe mucocutaneous drug reaction associated with significant morbidity and mortality. A previously developed SJS/TEN-specific severity-of-illness model (Score of Toxic Epidermal Necrolysis [SCORTEN]) has been reported to overestimate and underestimate SJS/TEN-related in-hospital mortality in various populations. OBJECTIVE: To derive a risk prediction model for in-hospital mortality among patients with SJS/TEN and to compare prognostic accuracy with the SCORTEN model in a multi-institutional cohort of patients in the United States. DESIGN, SETTING, AND PARTICIPANTS: Data from a multicenter cohort of patients 18 years and older treated for SJS/TEN between January 1, 2000, and June 1, 2015, were obtained from inpatient consult databases and electronic medical record systems at 18 medical centers in the United States as part of the Society for Dermatology Hospitalists. A risk model was derived based on data from 370 of these patients. Model discrimination (calculated as area under the receiver operating characteristic curve [AUC]) and calibration (calculated as predicted vs observed mortality, and examined using the Hosmer-Lemeshow goodness-of-fit statistic) were assessed, and the predictive accuracy was compared with that of SCORTEN. All analysis took place between December 2016 and April 2018. MAIN OUTCOMES AND MEASURES: In-hospital mortality. RESULTS: Among 370 patients (mean [SD] age 49.0 [19.1] years; 195 [52.7%] women), 54 (15.14%) did not survive to hospital discharge. Five covariates, measured at the time of admission, were independent predictors of in-hospital mortality: age in years (odds ratio [OR], 1.05; 95% CI, 1.02-1.07), body surface area (BSA) in percentage of epidermal detachment (OR, 1.02; 95% CI, 1.01-1.04), serum bicarbonate level below 20 mmol/L (OR, 2.90; 95% CI, 1.43-5.88), active cancer (OR, 4.40; 95% CI, 1.82-10.61), and dialysis prior to admission (OR, 15.94; 95% CI, 3.38-66.30). A severity-of-illness score was calculated by taking the sum of 1 point each for age 50 years or older, epidermal detachment greater than 10% of BSA, and serum bicarbonate level below 20 mmol/L; 2 points for the presence of active cancer; and 3 points for dialysis prior to admission. The score was named ABCD-10 (age, bicarbonate, cancer, dialysis, 10% BSA). The ABCD-10 model showed good discrimination (AUC, 0.816; 95% CI, 0.759-0.872) and calibration (Hosmer-Lemeshow goodness of fit test, P = .30). For SCORTEN, on admission, the AUC was 0.827 (95% CI, 0.774-0.879) and was not significantly different from that of the ABCD-10 model (P = .72). CONCLUSIONS AND RELEVANCE: In this cohort of patients with SJS/TEN, ABCD-10 accurately predicted in-hospital mortality, with discrimination that was not significantly different from SCORTEN. Additional research is needed to validate ABCD-10 in other populations. Future use of a new mortality prediction model may provide improved prognostic information for contemporary patients, including those enrolled in observational studies and therapeutic trials.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Noe MH, Rosenbach M, Hubbard RA, et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. JAMA Dermatol. 2019. PMID: 30840032. doi:10.1001/jamadermatol.2018.5605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。